CYDX yields 319.49% · JNJ yields 2.13%● Live data
📍 CYDX pulled ahead of the other in Year 1
Combined, CYDX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYDX + JNJ for your $10,000?
CYduct Diagnostics, Inc., a healthcare instrument company, develops and markets technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment, and management of disease and medical conditions. The company's products include breast endoscopy systems; 3-chip and 1-chip camera systems; cameras and accessories; endoscopic instruments, such as dissectors, graspers, scissors, needle holders, fan retractors, cautery instruments, and insufflation needles; and illumination series products, including fiber optic cables, light port adapters, light sources, and replacement lamps. It also offers insufflators; laparoscopic instruments, such as general surgery, lymphadenectomy, gynecology, and thorascopy instruments; rigid scopes and accessories, including laparoscopes, operative scopes, cystoscopes, and scope trays; trocar and cannula sets, cannulas, trocars, reducer sleeves, and seals; video carts; instrument handles that include insulated handles and non-insulated handles; and veterinary instrumentation. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was founded in 1986 and is based in Westport, Connecticut.
Full CYDX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.